They also will evaluate advances in imaging and current and emerging therapies for the treatment and management of retinal vein occlusion. Upon successful completion of this educational activity ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

(MENAFN- EIN Presswire) Leading companies such as Kodiak Sciences and Outlook Therapeutics are driving advancements in Retinal Vein Occlusion treatments to enhance patient care. LAS VEGAS , NV ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Lucentis is FDA-approved for the treatment of patients with wet age-related macular degeneration (AMD), macular edema ...

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to ...

But if you get proper treatment promptly ... retinal tears, retinal detachment, glaucoma, retinitis pigmentosa, and vein occlusion. All can threaten your sight if ignored. Here's what to know ...

A variety of retinal signs can occur in patients who have systemic vasculitides, or who experience complications of these diseases or their treatment ... rather than the veins, and these signs ...

The EYLEA HD results were consistent across patients with branch retinal vein occlusions ... of EYLEA HD in its pivotal trials. Ocular treatment-emergent adverse events (TEAEs) occurring in ...